The U.S. FDA has granted accelerated approval to EMRELIS™ (telisotuzumab vedotin-tllv) for treating adult patients with locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression who have undergone prior systemic therapy. High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined by an FDA-approved test. This approval is based on overall response rate and duration of response. Continued approval may depend on clinical benefit verification in confirmatory trials. AbbVie’s EMRELIS is the first and only treatment approved for this patient population.
— new from AbbVie News Center
